Jasper Therapeutics, Inc.: completed enrollment of IgAN cohort

What happened Jasper Therapeutics, Inc. (JSPR) announced on Oct 15, 2026 that it completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company issued a press release and filed a copy as Exhibit 99.1 to the Current Report on Form 8-K.

Key details

• Oct 15, 2026: press release announcing completion of enrollment of the IgAN cohort.
• Study: Phase 2 basket study evaluating vensobafusp alfa (KP104).
• The press release is filed as Exhibit 99.1 to the Current Report on Form 8-K.
• The event is reported under Item 8.01 (Other events).

Why it may matter This Form 8-K reports Item 8.01 (Other events), which covers the company’s press release announcing completion of enrollment of the IgAN cohort in its Phase 2 basket study evaluating vensobafusp alfa (KP104). A filing does not show why the insider traded or why the company acted.